XIO

xWire

Posts from every feed QUEST has found across the web — blogs, news, podcasts, channels and more.

The Medical News

from News-Medical.Net - Latest Medical News and Research from Around the World

New European real-world evidence supporting Pepaxti in heavily pretreated multiple myeloma to be presented at ASH 2026

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that two abstracts highlighting real-world clinical outcomes for Pepaxti (melflufen) in relapsed, refractory multiple myeloma (RRMM) have been accepted for presentation at the 68th American Society of Hematology (ASH) Annual Meeting, taking place in New Orleans, USA, December 12–15, 2026.

MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines

MRM Health, a clinical-stage biotech developing microbiome-based therapies for immune-mediated diseases, and Biocodex, an independent French pharmaceutical company with more than 70 years of experience in the microbiome field, today announced the launch of a strategic partnership to establish specialized manufacturing capabilities for live biotherapeutic products.

Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting

Evaxion A/S (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML), in a poster session at the American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, Louisiana, December 12-15, 2026.

Extreme heat and cold hit some people far harder, and it's not just about illness

Researchers analysing 285,444 adults in Finland and the UK found that excess mortality associated with extreme heat and cold was more than tenfold higher among people with both pre-existing medical conditions and socioeconomic disadvantage than among those with neither or only one vulnerability. Climate modelling suggested that warming from approximately 1°C to 4°C could increase the proportion of deaths attributable to extreme temperatures from around 1% to more than 5% in both countries.

DEBRA research invests in Topadur to advance small-molecule therapies for dystrophic Epidermolysis bullosa

DEBRA Research gGmbH, a global non-profit organization dedicated to advancing research and drug development for Epidermolysis bullosa (EB), and Topadur Pharma AG, a Swiss clinical-stage biopharmaceutical company, today announced an investment by DEBRA Research in Topadur to support a preclinical program exploring a new treatment approach for dystrophic Epidermolysis bullosa (DEB). DEB is one of the more severe forms of EB, characterized by extremely fragile skin and progressive, debilitating…

Prolific announces major new investments and partnerships with NantWorks and Zylidac Bio CDMO

On the heels of our exciting major investment and Nantworks partnership announcement last week, Prolific Machines is pleased to announce a great new partnership with Zylidac Bio, a fully integrated biologics CDMO located next door to us in San Francisco Bay Area, to scale up the production of Prolific's Optogentics-enabled cell lines for clinical and GMP manufacturing!